Intelligent Ultrasound Group plc
("Intelligent Ultrasound" or the "Company" or the "Group")
PDMR/PCA Dealing
Intelligent Ultrasound Group plc (AIM: IUG), the 'classroom to clinic' ultrasound company, specialising in artificial intelligence (AI) software and simulation, announces the following director & person closely associated share transactions.
The Company announces that Ian Whittaker, the Chief Commercial Officer and a Person Discharging Managerial Responsibilities of the Company ("PDMR"), transferred 81,000 Ordinary Shares in the Company for nil consideration on 23 March 2023 to a nominee account of which his wife is the beneficial owner.
Following these transactions, Ian Whittaker's interest in Ordinary Shares and that of his persons closely associated remains unchanged at 532,253 Ordinary Shares of 1p representing 0.16% of the total issued share capital of the Company.
This notification relates to transactions notified in accordance with the Market Abuse Regulation, further details below:
| NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Ian Whittaker |
| 2 | Reason for the notification | |
| a) | Position/status | Chief Commercial Officer, PDMR |
| b) | Initial notification/amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Full name of the entity | Intelligent Ultrasound Group plc |
| b) | Legal entity identifier code | 213800K4ZVWL4ZYQAZ70 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument | Ordinary shares in Intelligent Ultrasound plc with a nominal value of 1 pence each |
| b) | Identification Code | GB00BN791Q39 |
| c) | Nature of the transaction | Transfer to a nominee account |
| d) | Currency | GBP - British pound |
| e) | Price(s) and Volume(s) | Nil£ and 81,000 Ordinary Shares |
| f) | Aggregated information - Price - Volume - Total | N/A |
| g) | Date of transaction | 23 March 2023 |
| h) | Place of transaction | London Stock Exchange |
| NOTIFICATION OF TRANSACTIONS OF PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES | ||
| 1 | Details of the person discharging managerial responsibilities / person closely associated | |
| a) | Name | Sarah Whittaker |
| 2 | Reason for the notification | |
| a) | Position/status | PCA, Wife of Chief Operating Officer |
| b) | Initial notification/amendment | Initial notification |
| 3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
| a) | Full name of the entity | Intelligent Ultrasound Group plc |
| b) | Legal entity identifier code | 213800K4ZVWL4ZYQAZ70 |
| 4 | Details of the transaction(s) | |
| a) | Description of the financial instrument, type of instrument | Ordinary shares in Intelligent Ultrasound plc with a nominal value of 1 pence each |
| b) | Identification Code | GB00BN791Q39 |
| c) | Nature of the transaction | Receipt of shares to a nominee account |
| d) | Currency | GBP - British pound |
| e) | Price(s) and Volume(s) | Nil£ and 81,000 Ordinary Shares |
| f) | Aggregated information - Price - Volume - Total | N/A |
| g) | Date of transaction | 23 March 2023 |
| h) | Place of transaction | London Stock Exchange |
| Intelligent Ultrasound Group plc | |||
| Stuart Gall, CEO | Tel: +44 (0)29 2075 6534 | ||
| | | ||
| Cenkos Securities - Nominated Advisor and broker | Tel: +44 (0)20 7397 8900 | ||
| Giles Balleny / Max Gould (Corporate Finance) | | ||
| Michael Johnson / Julian Morse (Sales) | | ||
| | | ||
| Walbrook PR | Tel: +44 (0)20 7933 8780 or intelligentultrasound@walbrookpr.com | ||
| Anna Dunphy | Mob: +44 (0)7876 741 001 | ||
ABOUT INTELLIGENT ULTRASOUND GROUP
Intelligent Ultrasound (AIM: IUG) is one of the world's leading 'classroom to clinic' ultrasound companies, specialising in real-time hi-fidelity virtual reality simulation for the ultrasound training market ('classroom') and artificial intelligence-based clinical image analysis software tools for the diagnostic medical ultrasound market ('clinic'). Based in Cardiff in the UK and Atlanta in the US, the Group has two revenue streams:
Simulation
Real-time hi-fidelity ultrasound education and training through simulation. Our main products are the ScanTrainer obstetrics and gynaecology training simulator, the HeartWorks echocardiography training simulator, the BodyWorks Eve Point of Care and Emergency Medicine training simulator with Covid-19 module and the new BabyWorks Neonate and Paediatric training simulator. To date over 1,450 simulators have been sold to over 700 medical institutions around the world.
Clinical AI software
Deep learning-based algorithms to make ultrasound machines smarter and more accessible using our proprietary ScanNav ultrasound image analysis technology. Current products on the market utilising this technology are GE Healthcare's SonoLyst software that is incorporated in their Voluson Expert 22 and SWIFT ultrasound machines; ScanNav Anatomy PNB that simplifies ultrasound image interpretation by providing the user with real-time AI-based anatomy highlighting for a range of ultrasound guided regional anesthesia procedures; and NeedleTrainer that teaches real-time ultrasound-guided needling and incorporates ScanNav Anatomy PNB.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.